New Studies on Dexketoprofen

IF 0.2 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
J. Kuczynska, Angelika Pawlak, B. Nieradko-Iwanicka
{"title":"New Studies on Dexketoprofen","authors":"J. Kuczynska, Angelika Pawlak, B. Nieradko-Iwanicka","doi":"10.2478/phr-2021-0012","DOIUrl":null,"url":null,"abstract":"Abstract Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body. Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability. Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis. Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening. Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.","PeriodicalId":40385,"journal":{"name":"Polish Hyperbaric Research","volume":"75 1","pages":"69 - 86"},"PeriodicalIF":0.2000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish Hyperbaric Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/phr-2021-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body. Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability. Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis. Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening. Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.
右酮洛芬的新研究
摘要简介。地塞米松(DEX)属于非甾体抗炎药(NSAIDs),具有镇痛、抗炎和解热特性。DEX是酮洛芬(S+)的对映体,具有比酮洛芬更强的作用。即使在小剂量给药后,它也非常有效。DEX的治疗不会引起严重的副作用,而且身体还能耐受。目标该综述旨在寻找近年来关于DEX及其治疗效果、安全性和耐受性的原创科学出版物。方法对不早于2015年发表的科学文章进行了系统审查。使用来自PubMed、Google Scholar和Medline Complete数据库的材料。文献综述于2021年11月进行。在发现的出版物中,选择了28篇科学文章进行分析。结果和讨论。近年来,有许多关于DEX的出版物。分析了DEX治疗疼痛的新数据,并与其他药物和中间疗法进行了比较,综述了其与曲马多和硫秋水仙苷联合使用的最新报道,并探讨了DEX的一种新的缓释形式和该药物的新治疗应用。在分析了所有研究后,发现与其他药物相比,DEX产生了类似或更有效的镇痛作用,并减少了对急救药物的需求。此外,值得注意的是,在联合治疗中使用DEX远比单独服用要好,而且还被发现对提高癫痫阈值有效。与DEX相比,中间疗法在治疗疼痛症状方面取得了更高的效果。使用DEX治疗后出现的副作用不会危及生命。结论综述结果证实,DEX是一种非常好的镇痛药,比扑热息痛和双氯芬酸钠更有效,同时与右美托咪定和利多卡因具有相似的效果。DEX与曲马多或硫代秋水仙苷联合使用比单独使用这两种药物更有效。科学家们正在研究长效DEX,并正在寻找该药物在癫痫和肿瘤学中的新应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Polish Hyperbaric Research
Polish Hyperbaric Research PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
自引率
0.00%
发文量
6
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书